DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
December 21, 2023 08:15 ET
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (Nasdaq: DMK) (“DMK”), a commercial stage neuro-biotech company primarily focused on developing and commercializing...
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
November 28, 2023 08:05 ET
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for...
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023 07:30 ET
|
DMK Pharmaceuticals Corporation
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI®...
DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
November 13, 2023 10:52 ET
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for...
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
October 30, 2023 07:30 ET
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board...
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2023 16:15 ET
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Oct. 20, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage biopharmaceutical company, today announced that the compensation committee of the board...
DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
October 19, 2023 16:05 ET
|
DMK Pharmaceuticals Corporation
Seth Cohen is appointed Chief Financial Officer, bringing over thirty years of financial industry experience to DMK, and seasoned corporate lawyer John Dorbin assumes role of General Counsel Corporate...
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
September 07, 2023 12:00 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK...
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 21, 2023 09:15 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second...
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
August 04, 2023 13:43 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of...